Antibody therapy of cancer
Top Cited Papers
- 22 March 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 12 (4), 278-287
- https://doi.org/10.1038/nrc3236
Abstract
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.Keywords
This publication has 56 references indexed in Scilit:
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 2011
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and ImmunoescapeJournal of Clinical Oncology, 2010
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerThe New England Journal of Medicine, 2008
- A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptorsProceedings of the National Academy of Sciences of the United States of America, 2007